CD274 and neoplasm: During the rapidly evolving era of immunotherapy, PD‐L1 protein expression is widely used as biomarker for selection of appropriate candidates for immune checkpoint blockade in several tumor types (Reck et al., 2016; Reck et al., 2019), including TNBC (Emens et al., 2018; Schmid et al., 2018).